 |
 |
|
University of California, San Francisco | |
|
|
About UCSF | |
|
|
Search UCSF | |
|
|
UCSF Medical Center |
|
|
||||
        |
What Happens Here
Signs of Our Success
About the SchoolMission, School Profile, Accomplishments, History, Funding, Leadership, Administration, Board of Advisors Visit the SchoolMaps & Locations, Virtual Tour Information forProspective Students, Current Students, Alumni, Faculty and Staff Campus and UC ConnectionsThe UCSF School of Pharmacy is one of four health sciences schools, a graduate division, and a medical center at the University of California, San Francisco, which is one of 10 campuses in the UC system. |
Academic Programs and Admissions
FacultyContact information for and UCSF citations of the School's salaried faculty members. DepartmentsResearchAreas of the School's expertise, programs, facilities, services, and links. Partnerships
Other Education and Training |
|
© 2002-2009 The Regents of the University of California. See also Copyrights and Credits. About privacy. About accessibility. Contact us.
Takeda San Francisco, Inc., announced September 21, 2009 that that it has entered into a sponsored collaboration with UCSF to support antibody-related research in the laboratory of Charles Craik, PhD, faculty member in the Department of Pharmaceutical Chemistry, UCSF School of Pharmacy. Craik will be the principal investigator of the project, which will focus on therapeutic antibody discovery and development to an undisclosed target. 
Full Story:
Scientists from the UCSF School of Pharmacy's Department of Pharmaceutical Chemistry have been selected to lead a new federal initiative aimed at developing new classes of drugs to target cancer. Department Chair James Wells, PhD, with department faculty member Michelle Arkin, PhD, will lead UCSF's participation in the new National Cancer Institute initiative, called the Chemical Biology Consortium (CBC). The UCSF team will use small molecules to "search" the surface of cells for possible new "druggable" sites. At the heart of UCSF's CBC work will be the Small Molecule Discovery Center, which Wells directs. 
UCSF researcher Deanna Kroetz, PhD, discusses the impact of genetic differences on how an individual responds to drugs in a KQED Quest radio interview that aired September 14, 2009. Fellow members of the interview panel were UCSF Chancellor Susan Desmond-Hellmann, MD, MPH, and UCSF breast cancer surgeon Laura Esserman, MD, MBA. 
Breast cancer patients might not be getting full advantage from a genetic screening test for the protein known as HER2 to help determine if the use of trastuzumab (marketed as Herceptin) is the best course of treatment for them. For patients whose breast cancer cells produce excessive amounts of HER2, trastuzumab can be highly effective. These conclusions appear in the first major research report from the Center for Translational and Policy Research on Personalized Medicine (TRANSPERS) established in 2008 by the UCSF School of Pharmacy, Department of Clinical Pharmacy. Center Director Kathryn Phillips, PhD, was the lead author of the paper that appeared in Cancer, online September 14, 2009. Phillips and colleagues found that little evidence is available to determine whether all eligible patients are tested, how many are retested to confirm results, and how many with negative HER2 test results still receive trastuzumab. 